On April 29, Biovail Corp. , the Canadian specialty pharmaceutical company, saw its shares plummet over 20%, wiping almost a billion dollars from its market value in just one day. A rare sell recommendation from one of the sector's most highly regarded analysts, Jerry Treppel of Banc of America Securities, caused the dramatic slide. It later transpired that Treppel had a potential conflict of interest; he was accused of holding stock in Andrx Corp. , one of Biovail's strongest competitors, promoting Andrx to investors and trading in its options (albeit through a managed account, with trades instigated by the managing broker). And yet another Wall Street scandal ensued.
But what got lost amidst the scandal-mongering was that Treppel had raised some valid points about Biovail and in the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?